Trial Profile
Second phase 3 pivotal, six-month efficacy study of elagolix in patients with Uterine Fibroids
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2015
Price :
$35
*
At a glance
- Drugs Elagolix (Primary)
- Indications Uterine leiomyoma
- Focus Therapeutic Use
- 18 Sep 2015 New trial record
- 16 Sep 2015 According to AbbVie media release, company is planning to initiate this trial in the first quarter of 2016.